It is a pretty quiet start to the week (again) but a little less so than previous weeks. At least we have a GILD deal to think about, although not the one everyone was expecting (hoping for). While I certainly would like to see the sector rocket higher, there is something to be said for […]
April 1 Biotech Update
Yesterday was generally a good day for the sector but it is hard to feel particularly good about it. We certainly need more time to see if this is another rally that leads to additionally dumping of positions. We have been waiting for catalysts that would turn the sector but that is probably a false […]
March 24 Biotech Update
The week has not been ending how it started and this is always the risk with short covering rallies. Without real long term buyers, they are going to be susceptible to large swings. SMID biotechs that were up nicely from the lows are suddenly down 10%+ on a day on no news. While this is […]
March 22 Biotech Update
It looks like the sector did not fall off a cliff and perhaps has been finding some support. We still have the recurring question of whether this is real buying or simply short covering. As has been the case, I fall in the camp that this is short covering at least among the smaller caps. […]
March 17 Biotech Update
You are missing a lot of private interaction we are mostly using the private feed @CRGTrades to do so, the best way to be updated is to follow us through this link, please fill in all the info needed for easy confirmation! https://www.chimeraresearchgroup.com/twitter-page/ Well, I do not think we really learned anything new yesterday in […]
March 16 Biotech Update
We are again at a decision point in the sector where it seems we are close to making another leg lower. My base case has been that there is not another major leg lower but VRX combined with the proposed Medicare part B changes have really hit the sector. We still may stave off another […]
March 11 Biotech Update
The blast from the past continues as the market and sector continue to weaken. As cheap as large cap biotechs look it is hard to see a stock like CELG break below what was a trading range and not think it will re-test the previous lows in the lower $90s. While the market today started […]
March 9 Biotech Update
Yesterday was certainly a blast from the past with small caps getting crushed and large caps outperforming but only because they are down less than SMID. After the recent run it is not surprising that the run pauses and reverses at resistance. As one could imagine the bears will highlight this as the start of […]
March 7 Biotech Update
I hope everyone had a good weekend. We are off to a rather slow start with not a lot of meaningful news (again). We have a more positive sentiment background and likely the continued short covering rally, so that might be enough to move the sector higher. The trend that I want to watch this […]
March 2 Biotech Update
The market has a good rally off of the lows yesterday and despite still feeling concerned about the market it has actually had a nice rally in the second half of February. The problem is that two weeks of good price action is not nearly enough to get rid of the damage especially in the […]
February 29 Biotech Update
I would have expected more action to start the week but it has been pretty quiet. It looks like we are left to the sentiment tides once again as there is nothing I see on the news front that can make a dent in either direction. As such, I will spend today mainly talking about […]
February 22 Biotech Update
It is a good start to the week as the markets open green and everything seems to be heading higher. One could argue that the trend of selling the rallies has broken but I still think we need to decisively put in a higher low and higher high before we can get any confidence in […]
Dave-Trading – PFE
Pfizer Inc. (PFE)–NYSE *** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** Options are unfairly seen as risky, and many value investors avoid options out of fear. David Sobek appears to be […]
February 5 Biotech Update
The sector did OK during the pricing hearing but it was more of a mixed bag than across the board out- or under-performance. Today everything is down, so it is hard to see if there is any other effect from the hearing or the debate last night. We are still in a macro driven market […]
February 4 Biotech Update
Today is going to be an interesting day. Yes, there is the drug pricing testimony in Congress and that is simply a show and grandstanding that has no impact on the actual chances of changing policy. It will be good theater (unless you are already tired of seeing the same stories recycled everyday) but in […]
February 3 Biotech Update
The market remains tied to oil and while sentiment remains negative on oil it still has not made a new low. This is not to say that a new low is not coming but as long as it does not make a lower low, it is at least some positive for the market. Ultimately, we […]
February 1 Biotech Update
Different week but the same market. There remains a bias to the downside, although perhaps an optimist can see a slight outperformance of the sector. At the very least, it seems like the sector is not leading the market lower. We got some news this morning but the key this week will continue to be […]
January 27 Biotech Update
The sector finally caught a break with the macro headwinds seeming to pause only to get sector specific headwinds with Donald Trump talking about drug pricing. It was not clear exactly what he meant as the numbers he threw around for the savings from Medicaid were more than the Medicaid yearly drug expense (keeping in […]
January 14 Biotech Update
So the sector has been struggling a little during JPM. I think many hoped (including me) that good news out of JPM would be a nice catalyst to flip sector sentiment but we essentially saw the opposite with all news (good and bad) being sold. At this point, it is clear that the selling has […]
December 31 Biotech Update
I figured there would be a more positive bias as we headed into the end of the year but the market has seen some selling. Obviously volume is low but the new Clinton talk of drug prices plus the low volumes is probably not good for the sector. Just as the drug pricing issue was […]
